KR20230012469A - 바이러스 감염의 발생을 치료, 예방 또는 제한하기 위한 방법 및 조성물 - Google Patents
바이러스 감염의 발생을 치료, 예방 또는 제한하기 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR20230012469A KR20230012469A KR1020227035956A KR20227035956A KR20230012469A KR 20230012469 A KR20230012469 A KR 20230012469A KR 1020227035956 A KR1020227035956 A KR 1020227035956A KR 20227035956 A KR20227035956 A KR 20227035956A KR 20230012469 A KR20230012469 A KR 20230012469A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- occurrence
- composition
- treating
- viral infection
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 35
- 230000009385 viral infection Effects 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims description 25
- 241000700605 Viruses Species 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 230000008685 targeting Effects 0.000 claims abstract description 10
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 32
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 32
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 208000025721 COVID-19 Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 7
- 229940116852 myricetin Drugs 0.000 claims description 7
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 7
- 235000007743 myricetin Nutrition 0.000 claims description 7
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 6
- 229960001587 hesperetin Drugs 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- -1 fluorophenols Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 2
- 229940025878 hesperidin Drugs 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 1
- 229940075559 piperine Drugs 0.000 claims 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 1
- 235000019100 piperine Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 230000000241 respiratory effect Effects 0.000 abstract description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 239000003443 antiviral agent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- QWHUUWFQDNTHGB-UHFFFAOYSA-N 2-(3-chloro-4,5-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one Chemical compound C1=C(C=C(C(=C1O)O)Cl)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O QWHUUWFQDNTHGB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002787 myricetin Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990168P | 2020-03-16 | 2020-03-16 | |
| US62/990,168 | 2020-03-16 | ||
| PCT/US2021/022538 WO2021188520A1 (en) | 2020-03-16 | 2021-03-16 | Method and compositions for treating, preventing or limiting the occurrence of viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230012469A true KR20230012469A (ko) | 2023-01-26 |
Family
ID=77768366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227035956A KR20230012469A (ko) | 2020-03-16 | 2021-03-16 | 바이러스 감염의 발생을 치료, 예방 또는 제한하기 위한 방법 및 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230132782A1 (zh) |
| EP (1) | EP4121040A4 (zh) |
| JP (1) | JP2023518390A (zh) |
| KR (1) | KR20230012469A (zh) |
| CN (1) | CN115397410A (zh) |
| AU (1) | AU2021236622A1 (zh) |
| BR (1) | BR112022018504A2 (zh) |
| CA (1) | CA3172162A1 (zh) |
| WO (1) | WO2021188520A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230165831A1 (en) * | 2021-11-19 | 2023-06-01 | Impact Biolife Science, Inc. | Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers |
| CN117462539A (zh) * | 2023-12-26 | 2024-01-30 | 云南中医药大学 | 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1605335A (zh) * | 2003-05-30 | 2005-04-13 | 任启生 | 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物 |
| CN101701245B (zh) * | 2009-10-21 | 2013-06-19 | 中国科学院生物物理研究所 | 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法 |
| US20140194500A1 (en) * | 2013-01-08 | 2014-07-10 | Kookmin University Industry Academic Cooperation Foundation | Methods For Treating of SARS |
| US20210299088A1 (en) * | 2015-02-13 | 2021-09-30 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
| US10383842B2 (en) * | 2015-02-13 | 2019-08-20 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
| US10966954B2 (en) * | 2016-05-16 | 2021-04-06 | Global Biolife Inc. | Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders |
| US10987371B2 (en) * | 2017-06-09 | 2021-04-27 | Adaerata, Limited Partnership | Methods of preventing or treating filovirus and flavivirus diseases |
| CN113350330B (zh) * | 2020-03-06 | 2023-04-14 | 中国科学院上海药物研究所 | 杨梅素类化合物在制备防治新冠肺炎药物中的应用 |
| CN112546038A (zh) * | 2020-11-19 | 2021-03-26 | 澳门科技大学 | 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用 |
| CN113244217A (zh) * | 2021-06-25 | 2021-08-13 | 南开大学 | 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用 |
-
2021
- 2021-03-16 CN CN202180025427.5A patent/CN115397410A/zh active Pending
- 2021-03-16 AU AU2021236622A patent/AU2021236622A1/en active Pending
- 2021-03-16 US US17/911,455 patent/US20230132782A1/en active Pending
- 2021-03-16 CA CA3172162A patent/CA3172162A1/en active Pending
- 2021-03-16 KR KR1020227035956A patent/KR20230012469A/ko active Search and Examination
- 2021-03-16 JP JP2022555887A patent/JP2023518390A/ja active Pending
- 2021-03-16 EP EP21771167.0A patent/EP4121040A4/en active Pending
- 2021-03-16 WO PCT/US2021/022538 patent/WO2021188520A1/en unknown
- 2021-03-16 BR BR112022018504A patent/BR112022018504A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518390A (ja) | 2023-05-01 |
| BR112022018504A2 (pt) | 2022-11-29 |
| WO2021188520A1 (en) | 2021-09-23 |
| US20230132782A1 (en) | 2023-05-04 |
| EP4121040A4 (en) | 2024-07-17 |
| EP4121040A1 (en) | 2023-01-25 |
| CN115397410A (zh) | 2022-11-25 |
| CA3172162A1 (en) | 2021-09-23 |
| AU2021236622A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yousefi et al. | A global treatments for coronaviruses including COVID‐19 | |
| Dos Santos | Natural history of COVID-19 and current knowledge on treatment therapeutic options | |
| Tufan et al. | COVID-19, immune system response, hyperinflammation and repurposingantirheumatic drugs | |
| Zaidi et al. | The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review | |
| Bakadia et al. | Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine | |
| KR20230012469A (ko) | 바이러스 감염의 발생을 치료, 예방 또는 제한하기 위한 방법 및 조성물 | |
| CN112007163B (zh) | 用于治疗非洲猪瘟的药物组合物及其用途 | |
| Picot et al. | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 | |
| Konstantinidou et al. | Repurposing current therapeutic regimens against SARS-CoV-2 | |
| Tiwari et al. | Current trends in diagnosis and treatment strategies of COVID-19 infection | |
| Elkholy et al. | Ivermectin: a closer look at a potential remedy | |
| Pavlova et al. | A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19 | |
| Bostanghadiri et al. | COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development | |
| Mishra et al. | Coronavirus disease 2019 (COVID-19): origin, impact, and drug development | |
| Dianzani et al. | Nonspecific defenses | |
| WO2008101037A1 (en) | Method to treat inflammation | |
| Bablani et al. | COVID-19 & Effectiveness towards it’s available treatment | |
| CN114732804A (zh) | 一种含大麻二酚cbd提取物在新型冠状病毒肺炎的应用 | |
| Kwo et al. | HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) IN GENOTYPE 1 (G1) NULL RESPONDERS TO PEG-INTERFEON ALFA-2B (P) PLUS RIBAVIRIN (R) WHEN TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY: 62 | |
| US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
| Diyya et al. | Potential therapeutic avenues for COVID-19 therapy | |
| Azka et al. | Antiviral Therapy in Corona Virus Disease-19 (Covid-19) | |
| US20220273594A1 (en) | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | |
| Chaudhry et al. | A Review on the Advancements in COVID-19 Treatments and Vaccines | |
| Becker | A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity–hypothesis and implications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination |